IL1B and neoplasm: NLRP3 activation may improve anti-tumour immunity in malignancies with low levels of IL-1β production, while NLRP3 inhibition may help stop tumour growth in tumours with high amounts of IL-1β (Sharma and Kanneganti 2021).